Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases.

[1]  T. Geng,et al.  Predictive values of sST2 and IL-33 for heart failure in patients with acute myocardial infarction , 2021, Experimental biology and medicine.

[2]  M. Khalili.  Serum levels of interleukin (IL)-33 in patients with ischemic heart disease , 2018 .

[3]  M. Huibers,et al.  The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium , 2017, Journal of Cardiovascular Translational Research.

[4]  P. Veeraveedu,et al.  Ablation of IL‐33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress , 2017, Biochemical pharmacology.

[5]  A. Mebazaa,et al.  Prognostic stratification in pulmonary hypertension: A multi-biomarker approach. , 2017, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[6]  S. Xiong,et al.  IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis. , 2017, Journal of molecular and cellular cardiology.

[7]  A. Maisel,et al.  Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure , 2016, Arquivos brasileiros de cardiologia.

[8]  R. D. de Boer,et al.  Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[9]  Zhang Changjiang,et al.  The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway , 2015, PloS one.

[10]  S. Al-Salam,et al.  Acute myocardial infarction and myocardial ischemia-reperfusion injury: a comparison. , 2015, International journal of clinical and experimental pathology.

[11]  D. Ramji,et al.  The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. , 2015, Biochimica et biophysica acta.

[12]  Richard T. Lee,et al.  Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33 , 2015, Proceedings of the National Academy of Sciences.

[13]  R. D'Agostino,et al.  Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community. , 2014, Clinical chemistry.

[14]  Cong-Lin Liu,et al.  Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease , 2014, Coronary artery disease.

[15]  M. Humbert,et al.  Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. , 2014, Biochemical and biophysical research communications.

[16]  D. Pascual-Figal,et al.  Modulation of IL‐33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers , 2014, European journal of clinical investigation.

[17]  Zhi-Hong Liu,et al.  Plasma Soluble ST2 Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension , 2014, Clinical cardiology.

[18]  Peicheng Li,et al.  IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-κB pathways. , 2014, Molecular medicine reports.

[19]  K. Huber,et al.  Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome , 2014, PloS one.

[20]  Dong I. Lee,et al.  Cardiomyocyte-Specific Transforming Growth Factor &bgr; Suppression Blocks Neutrophil Infiltration, Augments Multiple Cytoprotective Cascades, and Reduces Early Mortality After Myocardial Infarction , 2014, Circulation research.

[21]  R. D. de Boer,et al.  Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. , 2014, Clinical chemistry.

[22]  D. Ramji,et al.  The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways , 2014, The international journal of biochemistry & cell biology.

[23]  A. D'Amico,et al.  IL-33/ST2 Pathway and Classical Cytokines in End-Stage Heart Failure Patients Submitted to Left Ventricular Assist Device Support: A Paradoxic Role for Inflammatory Mediators? , 2013, Mediators of inflammation.

[24]  Yu-hong Mi,et al.  Predicting value of serum soluble ST2 and interleukin‐33 for risk stratification and prognosis in patients with acute myocardial infarction , 2013, Chinese medical journal.

[25]  Sohail Q Khan,et al.  Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? , 2013, International journal of cardiology.

[26]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[27]  J. Januzzi.  ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside , 2013, Journal of Cardiovascular Translational Research.

[28]  G. Güvenen,et al.  Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction , 2013, The Korean journal of internal medicine.

[29]  Q. Tang,et al.  IL-33 Attenuates Anoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis by Inhibition of PKCβ/JNK Pathway , 2013, PloS one.

[30]  D. Yellon,et al.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target. , 2013, The Journal of clinical investigation.

[31]  Wei Xu,et al.  A20 (TNFAIP3) Alleviates CVB3-Induced Myocarditis via Inhibiting NF-κB Signaling , 2012, PloS one.

[32]  Hai-Feng Zhang,et al.  Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress , 2012, Journal of Translational Medicine.

[33]  Yongwei Yao,et al.  Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. , 2012, Cardiovascular research.

[34]  W. Mitzner,et al.  Th2 Regulation of Viral Myocarditis in Mice: Different Roles for TLR3 versus TRIF in Progression to Chronic Disease , 2011, Clinical & developmental immunology.

[35]  Ashley M Miller,et al.  The jackknife---a review , 1974 .

[36]  Ashley M. Miller,et al.  The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. , 2011, Pharmacology & therapeutics.

[37]  Leong L Ng,et al.  Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. , 2011, American heart journal.

[38]  M. Humbert,et al.  S154 Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension? , 2010, Thorax.

[39]  Ashley M. Miller,et al.  Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice , 2010, Circulation research.

[40]  Ashley M. Miller,et al.  IL-33 Reduces Macrophage Foam Cell Formation , 2010, The Journal of Immunology.

[41]  I. McInnes,et al.  Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.

[42]  I. McInnes,et al.  IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation1 , 2009, The Journal of Immunology.

[43]  Richard T. Lee,et al.  Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling , 2009, Circulation. Heart failure.

[44]  C. Gabay,et al.  Interleukin-33 Is Biologically Active Independently of Caspase-1 Cleavage* , 2009, The Journal of Biological Chemistry.

[45]  H. Kita,et al.  IL-33-activated dendritic cells induce an atypical TH2-type response. , 2009, The Journal of allergy and clinical immunology.

[46]  O. Muller,et al.  Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. , 2008, Journal of the American College of Cardiology.

[47]  J. Díez.  Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research. , 2008, Journal of the American College of Cardiology.

[48]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[49]  Sheetal Sharma,et al.  The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines1 , 2008, The Journal of Immunology.

[50]  Ashley M. Miller,et al.  IL-33 reduces the development of atherosclerosis , 2008, The Journal of experimental medicine.

[51]  Hanna Björk,et al.  ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. , 2008, Atherosclerosis.

[52]  D. Yellon,et al.  Myocardial reperfusion injury. , 2007, The New England journal of medicine.

[53]  M. Gadina,et al.  IL-33: A Sheep in Wolf’s Clothing? , 2007, Science's STKE.

[54]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[55]  A. Bayés‐Genís.  Hypertrophy and inflammation: too much for one heart. , 2007, European heart journal.

[56]  Delphine A. Lacorre,et al.  IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo , 2007, Proceedings of the National Academy of Sciences.

[57]  C. Dinarello.  An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. , 2005, Immunity.

[58]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[59]  M. Hayakawa,et al.  Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. , 2004, Biochimica et biophysica acta.

[60]  Wei Xu,et al.  Coxsackievirus Group B Type 3 Infection Upregulates Expression of Monocyte Chemoattractant Protein 1 in Cardiac Myocytes, Which Leads to Enhanced Migration of Mononuclear Cells in Viral Myocarditis , 2004, Journal of Virology.

[61]  D. Morrow,et al.  General cardiology: abstractsSerum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction☆ , 2004 .

[62]  E. S. Baekkevold,et al.  Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. , 2003, The American journal of pathology.

[63]  Richard T. Lee,et al.  Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.

[64]  M. Marber,et al.  Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. , 2002, Journal of the American College of Cardiology.

[65]  M. Kearney,et al.  Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management , 2001, Postgraduate medical journal.

[66]  S. Tominaga,et al.  Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. , 1999, Biochemical and biophysical research communications.

[67]  M. Itakura,et al.  Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. , 1999, European journal of biochemistry.

[68]  R. Klemenz,et al.  The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. , 1998, Journal of immunology.

[69]  I. McInnes,et al.  Selective Expression and Functions of Interleukin 18 Receptor on T Helper (Th) Type 1 but not Th2 Cells , 1998, The Journal of experimental medicine.

[70]  Andreas Radbruch,et al.  T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Ovize,et al.  A fresh look at reperfusion injury. , 1998, Cardiovascular research.

[72]  F. Liew,et al.  Selective Expression of a Stable Cell Surface Molecule on Type 2 but Not Type 1 Helper T Cells , 1998, The Journal of experimental medicine.

[73]  R. Klemenz,et al.  Transcription of the Interleukin-1 Receptor-related T1 Gene Is Initiated at Different Promoters in Mast Cells and Fibroblasts (*) , 1996, The Journal of Biological Chemistry.

[74]  M. Minnich,et al.  ST2/T1 Protein Functionally Binds to Two Secreted Proteins from Balb/c 3T3 and Human Umbilical Vein Endothelial Cells but Does Not Bind Interleukin 1 (*) , 1995, The Journal of Biological Chemistry.

[75]  H. Pouleur.  Role of neurohormones in ventricular adaptation and failure. , 1994, The American journal of cardiology.

[76]  M. Busslinger,et al.  Alternative promoter usage of the Fos‐responsive gene Fit‐1 generates mRNA isoforms coding for either secreted or membrane‐bound proteins related to the IL‐1 receptor. , 1994, The EMBO journal.

[77]  S. Tominaga,et al.  Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1 , 1993, FEBS letters.

[78]  B. Swynghedauw,et al.  Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. , 1993, The American journal of cardiology.

[79]  E. Braunwald,et al.  Myocardial reperfusion: a double-edged sword? , 1985, The Journal of clinical investigation.

[80]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.

[81]  F. Zouein,et al.  IL-33 ( Interleukin 33 ) / sST 2 ( Soluble Suppression of Tumorigenicity 2 ) Axis in Hypertension and Heart Failure , 2018 .

[82]  Hiroki Sato,et al.  Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[83]  Richard T. Lee,et al.  Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. , 2012, Clinical chemistry.